Physician

Brent M Skiver, DO

According to 2025 Medicare claims, Brent Skiver, DO (NPI: 1669764064) practices hematology/oncology in the Asheville, NC market, with the plurality of this provider's patient population coming from Buncombe, NC. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 28806-2316. Skiver is affiliated with the Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Skiver's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 866 traditional Medicare patients, billed 129,905 HCPCS/CPT codes, and received $2,847,479 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,270 prescription claims across 310 beneficiaries totaling $10,013,630 in drug costs, led by Revlimid (Lenalidomide). DME data shows 50 claims. Open Payments data shows 31 records totaling $3,208. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $86,822 to $2,847,479. Similarly, Part D prescription costs have moved sharply higher in recent years, from $16,547 to $10,013,630. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	393	1,068	$86,822
2016	198	552	$44,547
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	89	151	$10,716
2020	544	72,204	$1,181,162
2021	567	85,650	$2,153,950
2022	642	93,535	$1,398,738
2023	740	120,370	$1,685,898
2024	866	129,905	$2,847,479

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	80	197	$16,547
2016	39	120	$10,372
2017	N/R	19	$2,849
2018	N/R	14	$181
2019	39	91	$99,196
2020	117	589	$1,563,300
2021	141	853	$2,417,022
2022	201	1,235	$4,245,288
2023	229	1,568	$5,190,905
2024	310	2,270	$10,013,630

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$1,129
2016	N/R	61	$1,342
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	13	$2,216
2021	N/R	52	$33,882
2022	N/R	12	$229
2023	N/R	30	$7,287
2024	N/R	50	$1,457

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	126	396	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	330	601	$86
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	298	422	$12
36415	Insertion of needle into vein for collection of blood sample	569	1,201	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	583	1,379	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	151	4,221	$2,482,095
Imbruvica	Ibrutinib	60	1,686	$963,644
Lenalidomide	Lenalidomide	53	1,484	$774,788
Cabometyx	Cabozantinib S-Malate	27	810	$676,157
Calquence	Acalabrutinib Maleate	49	1,470	$607,136

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$924
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$3,208	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brent M. Skiver, DO?

Tedicare shows public-source Medicare data for Brent M. Skiver, DO (NPI 1669764064), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brent M. Skiver, DO have ACO affiliation data?

Brent M. Skiver, DO is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to Brent M. Skiver, DO?

Brent M. Skiver, DO is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Brent M. Skiver, DO have Open Payments data?

Brent M. Skiver, DO has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.